The philosophy of Polaris Venture Partners can be summed up simply: diversity is good. That's why about a third of the investments Polaris has made from the $80 million fund raised at its founding in 1996 is in the life sciences; two-thirds are in information technology.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Multi-blockbuster falls short in a giant cell arteritis study.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
